Osteosclerotic plasma cell myeloma
Cancer of plasma cells characterized by osteosclerosis
Osteosclerotic plasma cell myeloma | |
---|---|
Synonyms | N/A |
Pronounce | N/A |
Field | Hematology and oncology |
Symptoms | Bone pain, fatigue, fractures |
Complications | Amyloidosis, kidney disease, pathologic fractures, anemia, infections, nerve damage |
Onset | Gradual |
Duration | Long term |
Types | N/A |
Causes | Unknown |
Risks | Obesity, genetic predisposition |
Diagnosis | Blood test, urine test, bone marrow biopsy, medical imaging |
Differential diagnosis | N/A |
Prevention | N/A |
Treatment | Steroids, chemotherapy, stem cell transplantation, bisphosphonates, radiation therapy |
Medication | N/A |
Prognosis | Variable based on stage and treatment |
Frequency | Rare |
Deaths | N/A |
Osteosclerotic plasma cell myeloma is a rare subtype of plasma cell neoplasm characterized by osteosclerosis, a condition in which abnormal hardening occurs in the bones. This variant is distinct from other forms of multiple myeloma due to its association with bone formation abnormalities and fibrotic changes in the bone trabeculae.
Pathophysiology[edit | edit source]
Osteosclerotic plasma cell myeloma involves the proliferation of abnormal plasma cells within the bone marrow, which leads to the replacement of normal bone marrow elements. Unlike traditional osteolytic lesions seen in classic multiple myeloma, this subtype is marked by osteosclerosis, resulting in increased bone density. These changes are due to the interaction between cancerous plasma cells and osteoblasts, the cells responsible for bone formation.
The disease is also linked to excessive production of monoclonal antibodies by plasma cells, which can cause hyperviscosity syndrome, kidney damage, and immune suppression.
Clinical Features[edit | edit source]
Common symptoms include:
- Persistent bone pain, often in the spine, ribs, and pelvis
- Fatigue caused by anemia
- Pathologic fractures due to weakened bone structures
- Increased susceptibility to infections due to impaired immune function
Patients may also present with systemic complications such as hypercalcemia and kidney dysfunction.
Diagnosis[edit | edit source]
Diagnosis is typically made through a combination of:
- Blood tests to detect abnormal proteins (e.g., M protein) and assess kidney function
- Urine tests to identify Bence Jones proteins
- Bone marrow biopsy to evaluate plasma cell infiltration
- Medical imaging techniques like X-rays, CT scans, and MRI to identify osteosclerotic changes
In some cases, PET scans are used to assess the extent of disease spread.
Associated Conditions[edit | edit source]
- Lymph Node Changes
In osteosclerotic plasma cell myeloma, lymph nodes may exhibit changes resembling those seen in Castleman disease, a rare condition characterized by abnormal growth of lymphoid tissue.
- POEMS Syndrome
This subtype is frequently associated with POEMS syndrome, which stands for:
- **P**olyneuropathy (nerve damage causing weakness or numbness)
- **O**rganomegaly (enlargement of organs such as the liver or spleen)
- **E**ndocrinopathy (hormonal imbalances, such as diabetes or hypothyroidism)
- **M**onoclonal gammopathy (presence of abnormal monoclonal proteins)
- **S**kin changes (including thickening, hyperpigmentation, or increased hair growth)
Treatment[edit | edit source]
Treatment options for osteosclerotic plasma cell myeloma include:
- **Chemotherapy**: Standard regimens to reduce plasma cell proliferation
- **Steroids**: To manage inflammation and enhance the effects of chemotherapy
- **Stem cell transplantation**: For eligible patients, this offers the potential for long-term remission
- **Bisphosphonates**: To strengthen bones and reduce the risk of fractures
- **Radiation therapy**: Targeted treatment for localized bone pain or lesions
Prognosis[edit | edit source]
The prognosis for osteosclerotic plasma cell myeloma varies depending on the stage of the disease and response to treatment. While some patients achieve remission, others may experience disease progression. Early diagnosis and comprehensive management improve outcomes.
Epidemiology[edit | edit source]
Osteosclerotic plasma cell myeloma is a rare condition, representing a small fraction of multiple myeloma cases. It is more commonly diagnosed in older adults and shows a slight male predominance.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD